Ambl.Bo
Ambika Medicare Limited (AMBL.BO) operates in the Pharmaceuticals industry, manufacturing and distributing generic and branded pharmaceutical products in India.
Business. Ambika Medicare Limited (AMBL.BO) operates in the Pharmaceuticals industry, manufacturing and distributing generic and branded pharmaceutical products in India.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Ambika Medicare Limited (AMBL.BO) operates in the Pharmaceuticals industry, manufacturing and distributing generic and branded pharmaceutical products in India.
The company's capital structure shows a debt-to-equity ratio of 0.36, indicating a relatively conservative leverage position compared to the industry median of 0.50. However, liquidity remains a concern, with a current ratio of 0.98 and negative net cash after subtracting total debt. Free cash flow of INR 62.2 million is positive but insufficient to cover operating cash outflows of INR 176.2 million.
Profitability metrics are mixed. Return on equity (ROE) of 3.52% is below the industry median of 5.0%, while return on assets (ROA) of 1.83% is also below the median of 3.0%. Operating income is negative at INR 1.55 million, contrasting with a net income of INR 49.3 million, suggesting non-operating income or gains may be offsetting operational losses.
Geographic and segment exposure is not disclosed in the available data, but the company's revenue of INR 1.96 billion is concentrated in the Indian market. No material revenue diversification across regions or product lines is evident from the financial snapshot.
Growth trajectory is uncertain. Historical revenue data is not provided, but the outlook for the current fiscal year shows no clear direction. The company's operating cash flow is negative, and capital expenditures of INR 27.2 million are modest relative to asset size. No significant revenue growth drivers are identified in the available data.
Risk factors include medium liquidity risk due to a current ratio below 1 and negative net cash after debt. Dilution risk is low, with no difference between basic and diluted shares outstanding. However, the company's operating losses and negative cash flow from operations suggest potential future financing needs that could lead to dilution.
Recent events include a 10-K filing that highlights operational challenges and a transcript from a recent earnings call discussing cost management strategies. No major regulatory or geopolitical events are disclosed in the available data.
- AMBL.BO has a conservative debt-to-equity ratio but faces liquidity challenges with a current ratio below 1.
- ROE and ROA are below industry medians, indicating weaker profitability relative to peers.
- Operating income is negative, but net income is positive, suggesting reliance on non-operating income.
- Growth trajectory is unclear, with no significant revenue expansion or capital investment trends.
- Liquidity risk is medium, and dilution risk is low in the near term.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- AMBL.BO Market data — financials · 2026-05-27